ClinicalTrials.gg

Program

anbenitamab

Also written as “KN026”, “KN026 combination” and “Recombinant Humanized Bispecific antibody against HER2,KN026”.

Its studies are mostly in Breast Neoplasms · Stomach Neoplasms, led by 2 companies.

Furthest: phase 3, since Apr 22, 201912 company-led studies, 7 open or runningNext primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology61 open or runningphase 2since Apr 22, 2019Aug 3, 2018none ahead
CSPC Pharmaceutical Group66 open or runningphase 3since Jun 14, 2022Jun 14, 2022Dec 16, 2026phase 3 · NCT06747338
  • Named in CSPC Pharmaceutical Group’s own pipeline as anbenitamab (KN026), phase 4, as of Aug 20, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2018First study: phase 1 study in Breast NeoplasmsNew to Alphamab OncologyAlphamab Oncology · NCT03619681 · 63 enrolled · China
  2. Feb 18, 2019Phase 1 study in Breast NeoplasmsAlphamab Oncology · NCT03847168 · 22 enrolled · United States
  3. Apr 22, 2019Phase 2 study in Gastric/Gastroesophageal Junction CancerAlphamab Oncology · NCT03925974 · 45 enrolled · China
  4. Nov 1, 2019Phase 2 study in Breast NeoplasmsAlphamab Oncology · NCT04165993 · 68 enrolled · China
  5. Aug 18, 2020Phase 2 study in HER2-positive Solid TumorsAlphamab Oncology · NCT04521179 · 102 enrolled · China
  6. May 6, 2021Phase 2 study in Breast NeoplasmsAlphamab Oncology · NCT04881929 · 30 enrolled · China
  7. Jun 14, 2022CSPC Pharmaceutical Group's first study: phase 3 study in Stomach NeoplasmsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05427383 · 286 planned · China
  8. Apr 20, 2023Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT05838066 · 880 planned · China
  9. Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338 · 520 enrolled · China
  10. May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
  11. Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533 · 490 planned
  12. Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460 · 1,800 planned · China

Ahead

  1. Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT06747338
  2. Jun 30, 2028Primary completion: phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771
  3. Jun 30, 2032Primary completion: phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533
  4. Aug 7, 2034Primary completion: phase 3 study in Resectable HER2-positive Breast CancerCSPC Pharmaceutical Group · NCT07441460

TargetBeta

“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HE…”NCIt, read by Claude
“An engineered Fc-based heterodimeric bispecific monoclonal antibody, derived from trastuzumab and pertuzumab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2;”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07441460Resectable HER2-positive Breast Cancer · China3RecruitingCSPC Pharmaceutical GroupAug 7, 20341,800
NCT07332533HER2-positive Gastric Cancer3Not yet recruitingCSPC Pharmaceutical GroupJun 30, 2032490
NCT06998771HER2-positive Gastric Cancer2Not yet recruitingCSPC Pharmaceutical GroupJun 30, 2028153
NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China3Active, not recruitingCSPC Pharmaceutical GroupDec 16, 2026520
NCT05838066Breast Neoplasms · China3RecruitingCSPC Pharmaceutical GroupJul 31, 2025880
NCT05427383Stomach Neoplasms · China3RecruitingCSPC Pharmaceutical GroupNov 2025286
NCT04881929Breast Neoplasms · China2UNKNOWNAlphamab OncologyNov 15, 202230
NCT04521179HER2-positive Solid Tumors · China2CompletedAlphamab OncologyJan 12, 2022102
NCT04165993Breast Neoplasms · China2Active, not recruitingAlphamab OncologyMay 27, 202168
NCT03925974Gastric/Gastroesophageal Junction Cancer · China2CompletedAlphamab OncologyMay 31, 202245
NCT03847168Breast Neoplasms · United States1UNKNOWNAlphamab OncologyDec 31, 202222
NCT03619681Breast Neoplasms · China1CompletedAlphamab OncologyJun 30, 202263

How it is read

Names in the registry

  • “KN026”, 7 entries
  • “KN026 combination”, 2 entries
  • “Recombinant Humanized Bispecific antibody against HER2,KN026”, 1 entry
  • “KN026 10 mg/kg QW”, 1 entry
  • “KN026 20 mg/kg Q2W”, 1 entry

Codes read as this program: KN026.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.